Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Obesity Surgery
Erschienen in: Obesity Surgery 5/2019

22.02.2019 | Review Article

Changes in Gut Microbiota and Hormones After Bariatric Surgery: a Bench-to-Bedside Review

verfasst von: Mohsen Tabasi, Fatemeh Ashrafian, Jamil Kheirvari Khezerloo, Sahar Eshghjoo, Ava Behrouzi, Seyed Alireza Javadinia, Farid Poursadegh, Sana Eybpoosh, Sara Ahmadi, Amin Radmanesh, Ahmadreza Soroush, Seyed Davar Siadat

Erschienen in: Obesity Surgery | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Overweight and obesity are among the most prevalent non-communicable diseases which are generally treated successfully by bariatric or sleeve surgery. There are evidences affirming that sleeve surgery can manipulate the pH of the stomach and interact with the metabolism of fatty acids, carbohydrates, and bile acid transfer, leading to the overgrowth of gut microbiota. Therefore, this study aims to review the changes in gut microbiota and hormones after bariatric surgery.
Literatur
1.
Tsukumo DM, Carvalho BM, Carvalho Filho MA, et al. Translational research into gut microbiota: new horizons on obesity treatment: updated 2014. Arch Endocrinol Metab. 2015;59(2):154–60.CrossRef
2.
Moran CP, Shanahan F. Gut microbiota and obesity: role in aetiology and potential therapeutic target. Best Pract Res Clin Gastroenterol. 2014;28(4):585–97.CrossRef
3.
Sekirov I, Russell SL, Antunes LCM, et al. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859–904.CrossRef
4.
Patterson E, Ryan PM, Cryan JF, et al. Gut microbiota, obesity and diabetes. Postgrad Med J. 2016.
5.
Carding S, Verbeke K, Vipond DT, et al. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26(1):26191.PubMed
6.
Ferreira CM, Vieira AT, Vinolo MAR, et al. The central role of the gut microbiota in chronic inflammatory diseases. J Immunol Res. 2014;2014.
7.
Kennedy PJ, Cryan JF, Dinan TG, et al. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroenterol: WJG. 2014;20(39):14105–25.CrossRef
8.
Karlsson F, Tremaroli V, Nielsen J, et al. Assessing the human gut microbiota in metabolic diseases. Diabetes. 2013;62(10):3341–9.CrossRef
9.
Bisgaard H, Li N, Bonnelykke K, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol. 2011;128(3):646–52.e5.CrossRef
10.
Calapkorur S, Köksal E. The relation between laparoscopic sleeve gastrectomy and ghrelin. Int J Med Res Health Sci. 2017;6(7):29–35.
11.
Meek CL, Lewis HB, Reimann F, et al. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides. 2016;77:28–37.CrossRef
12.
Yousseif A, Emmanuel J, Karra E, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014;24(2):241–52.CrossRef
13.
Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247(3):401–7.CrossRef
14.
Jacobsen SH, Olesen S, Dirksen C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012;22(7):1084–96.CrossRef
15.
Dirksen C, Jørgensen N, Bojsen-Møller K, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes. 2013;37(11):1452–9.CrossRef
16.
Sundbom M, Holdstock C, Engström BE, et al. Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg. 2007;17(3):304–10.CrossRef
17.
Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55(7):2025–31.CrossRef
18.
Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(7):2479–85.CrossRef
19.
Tsoli M, Chronaiou A, Kehagias I, et al. Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surg Obes Relat Dis. 2013;9(5):667–77.CrossRef
20.
Stenström B, Zhao C-M, Tømmerås K, et al. Is gastrin partially responsible for body weight reduction after gastric bypass? Eur Surg Res. 2006;38(2):94–101.CrossRef
21.
Laferrere B, Swerdlow N, Bawa B, et al. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010;95(8):4072–6.CrossRef
22.
Farooqi SI. Genetic, molecular and physiological mechanisms involved in human obesity: Society for Endocrinology Medal Lecture 2012. Clin Endocrinol. 2015;82(1):23–8.CrossRef
23.
Sørensen T, Price RA, Stunkard AJ, et al. Genetics of obesity in adult adoptees and their biological siblings. Bmj. 1989;298(6666):87–90.CrossRef
24.
Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–32.CrossRef
25.
Ameer F, Scandiuzzi L, Hasnain S, et al. De novo lipogenesis in health and disease. Metab Clin Exp. 2014;63(7):895–902.CrossRef
26.
Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med. 2007;13(7):803–11.CrossRef
27.
Farooqi IS, Keogh JM, Yeo GS, et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348(12):1085–95.CrossRef
28.
Asai M, Ramachandrappa S, Joachim M, et al. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. Science. 2013;341(6143):275–8.CrossRef
29.
Yeo GS, Hung C-CC, Rochford J, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci. 2004;7(11):1187–9.CrossRef
30.
Ramachandrappa S, Raimondo A, Cali AM, et al. Rare variants in single-minded 1 (SIM1) are associated with severe obesity. J Clin Invest. 2013;123(7):3042–50.CrossRef
31.
Faivre L, Cormier-Daire V, Lapierre J, et al. Deletion of the SIM1 gene (6q16. 2) in a patient with a Prader-Willi-like phenotype. J Med Genet. 2002;39(8):594–6.CrossRef
32.
Goldstone AP. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab. 2004;15(1):12–20.CrossRef
33.
Pearce LR, Atanassova N, Banton MC, et al. KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation. Cell. 2013;155(4):765–77.CrossRef
34.
Peterson J, Garges S, Giovanni M, et al. The NIH human microbiome project. Genome Res. 2009;19(12):2317–23.CrossRef
35.
Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007;449(7164):804–10.CrossRef
36.
Boulangé CL, Neves AL, Chilloux J, et al. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8(1):42.CrossRef
37.
Quigley EM. Gut bacteria in health and disease. Gastroenterol Hepatol. 2013;9(9):560–9.
38.
Beaugerie L, Petit J-C. Antibiotic-associated diarrhoea. Best Pract Res Clin Gastroenterol. 2004;18(2):337–52.CrossRef
39.
Hugon P, Dufour J-C, Colson P, et al. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis. 2015;15(10):1211–9.CrossRef
40.
Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–36.CrossRef
41.
Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3.CrossRef
42.
Khanna S, Tosh PK, editors. A clinician’s primer on the role of the microbiome in human health and disease. Mayo Clinic Proceedings. Elsevier; 2014.
43.
Armougom F, Henry M, Vialettes B, et al. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and methanogens in anorexic patients. PLoS One. 2009;4(9):e7125.CrossRef
44.
Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci. 2009;106(7):2365–70.CrossRef
45.
Pedersen HK, Gudmundsdottir V, Nielsen HB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535(7612):376–81.CrossRef
46.
Murphy R, Stewart A, Braithwaite I, et al. Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. Int J Obes. 2014;38(8):1115–9.CrossRef
47.
Ajslev T, Andersen C, Gamborg M, et al. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int J Obes. 2011;35(4):522–9.CrossRef
48.
Trasande L, Blustein J, Liu M, et al. Infant antibiotic exposures and early-life body mass. Int J Obes. 2013;37(1):16–23.CrossRef
49.
Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–8.CrossRef
50.
Muegge BD, Kuczynski J, Knights D, et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science. 2011;332(6032):970–4.CrossRef
51.
Walker AW, Ince J, Duncan SH, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011;5(2):220–30.CrossRef
52.
David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–63.CrossRef
53.
Xu Z, Knight R. Dietary effects on human gut microbiome diversity. Br J Nutr. 2015;113(S1):S1–5.CrossRef
54.
Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23.CrossRef
55.
Cani PD, Lecourt E, Dewulf EM, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr. 2009;90(5):1236–43.CrossRef
56.
Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2009;89(6):1751–9.CrossRef
57.
Bäckhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307(5717):1915–20.CrossRef
58.
Payne AN, Chassard C, Banz Y, et al. The composition and metabolic activity of child gut microbiota demonstrate differential adaptation to varied nutrient loads in an in vitro model of colonic fermentation. FEMS Microbiol Ecol. 2012;80(3):608–23.CrossRef
59.
Bäckhed F, Manchester JK, Semenkovich CF, et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci. 2007;104(3):979–84.CrossRef
60.
61.
Kushner RF, Kahan S. Introduction: the state of obesity in 2017. Med Clin. 2018;102(1):1–11.
62.
Chaldakov GN. Obesity: an inside versus outside view Jimmy Bell and the Little Prince A science-in-fiction dedicated to World Obesity Day 2017. Scr Sci Vox Stud. 2017;1(1):13–7.
63.
Delzenne NM, Cani PD, Neyrinck AM. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: experimental data. J Nutr. 2007;137(11):2547S–51S.CrossRef
64.
Goldberg RF, Austen WG, Zhang X, et al. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci. 2008;105(9):3551–6.CrossRef
65.
Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49(5):565–71.CrossRef
66.
Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36–46.CrossRef
67.
Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Prev Biomark. 2007;16(12):2533–47.CrossRef
68.
Jahansouz C, Staley C, Bernlohr DA, et al. Sleeve gastrectomy drives persistent shifts in the gut microbiome. Surg Obes Relat Dis. 2017;13(6):916–24.CrossRef
69.
Kim T, Holleman CL, Ptacek T, et al. Duodenal endoluminal barrier sleeve alters gut microbiota of ZDF rats. Int J Obes. 2017;41(3):381–9.CrossRef
70.
Tremaroli V, Karlsson F, Werling M, et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 2015;22(2):228–38.CrossRef
71.
Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242–9.CrossRef
72.
Penney N, Kinross J, Newton R, et al. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes. 2015;39(11):1565–74.CrossRef
73.
Palleja A, Kashani A, Allin KH, et al. Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Med. 2016;8(1):67.CrossRef
74.
Kong L-C, Tap J, Aron-Wisnewsky J, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013;98(1):16–24.CrossRef
75.
Liou AP, Paziuk M, Luevano J-M, et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013;5(178):178ra41.CrossRef
76.
Ishida RK, Faintuch J, Paula AM, et al. Microbial flora of the stomach after gastric bypass for morbid obesity. Obes Surg. 2007;17(6):752–8.CrossRef
77.
Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2012;9(10):590–8.CrossRef
Metadaten
Titel
Changes in Gut Microbiota and Hormones After Bariatric Surgery: a Bench-to-Bedside Review
verfasst von
Mohsen Tabasi
Fatemeh Ashrafian
Jamil Kheirvari Khezerloo
Sahar Eshghjoo
Ava Behrouzi
Seyed Alireza Javadinia
Farid Poursadegh
Sana Eybpoosh
Sara Ahmadi
Amin Radmanesh
Ahmadreza Soroush
Seyed Davar Siadat
Publikationsdatum
22.02.2019
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 5/2019
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-019-03779-7

Weitere Artikel der Ausgabe 5/2019

Obesity Surgery 5/2019 Zur Ausgabe

Biography

Dr. Barry Fisher

Original Contributions

Impact of Pyloric Injection of Magnesium Sulfate-Lidocaine Mixture on Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy: a Randomized-Controlled Trial

Correction

Correction to: Massive Gastrointestinal Bleeding Due to Splenic Artery Erosion by a PigTail Drain in a Post Sleeve Gastrectomy Leak: a Case Report

Letter to the Editor

Bariatric Surgery in the Elderly Patient: Safety and Short-Time Outcome. A Case Match Analysis: Letter to the Editor

Letter to Editor/LED Reply

Reply to “The Assessment of a Predictive Risk and a Decrease Postoperative Complication Following Body Contouring Surgery after Massive Weight Loss”

Video Submission

Umbilical Single-Port Sleeve Gastrectomy as a Standardized Procedure: How to Do It? (Video)

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.